Michael D Pak

Array ( [id] => 10318589 [patent_doc_number] => 20150203589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'FUSION PROTEINS AND METHODS THEREOF' [patent_app_type] => utility [patent_app_number] => 14/604530 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 108 [patent_no_of_words] => 65999 [patent_no_of_claims] => 60 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14604530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10317293 [patent_doc_number] => 20150202296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'METHOD FOR ADMINISTERING GLP-1 MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/603239 [patent_app_country] => US [patent_app_date] => 2015-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14680 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11290797 [patent_doc_number] => 20160340729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'METHODS FOR DEFINING AND PREDICTING IMMUNE RESPONSE TO ALLOGRAFT' [patent_app_type] => utility [patent_app_number] => 15/110589 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 18785 [patent_no_of_claims] => 75 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15110589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15422579 [patent_doc_number] => 10544203 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Human FGFR2B extracellular domain and nucleic acid for coding same [patent_app_type] => utility [patent_app_number] => 15/106633 [patent_app_country] => US [patent_app_date] => 2014-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 8261 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15106633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10317246 [patent_doc_number] => 20150202249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 14/575065 [patent_app_country] => US [patent_app_date] => 2014-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14769 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14575065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10290710 [patent_doc_number] => 20150175709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'Inotropic Antibodies And Therapeutic Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/574310 [patent_app_country] => US [patent_app_date] => 2014-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15227 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14574310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10263307 [patent_doc_number] => 20150148304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome' [patent_app_type] => utility [patent_app_number] => 14/523341 [patent_app_country] => US [patent_app_date] => 2014-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8221 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14523341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11251392 [patent_doc_number] => 09476892 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-25 [patent_title] => 'Composition and method for measuring thallium influx and efflux' [patent_app_type] => utility [patent_app_number] => 14/521346 [patent_app_country] => US [patent_app_date] => 2014-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12052 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14521346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9799475 [patent_doc_number] => 20150011419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-08 [patent_title] => 'SYSTEMS AND METHODS FOR CHARACTERIZING LUPUS ERYTHEMATOSUS' [patent_app_type] => utility [patent_app_number] => 14/496651 [patent_app_country] => US [patent_app_date] => 2014-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8333 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14496651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11033217 [patent_doc_number] => 20160230173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-11 [patent_title] => 'METHODS FOR OVERCOMING GLUCOCORTICOID RESISTANCE AND FOR DETERMINING GLUCOCORTICOID RESISTANCE POTENTIAL IN CANCER' [patent_app_type] => utility [patent_app_number] => 15/022464 [patent_app_country] => US [patent_app_date] => 2014-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 19629 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15022464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15356111 [patent_doc_number] => 10526660 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Methods for evaluating and treating Waldenstrom's macroglobulinemia [patent_app_type] => utility [patent_app_number] => 15/021323 [patent_app_country] => US [patent_app_date] => 2014-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 19189 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15021323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9916722 [patent_doc_number] => 20150071923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/485620 [patent_app_country] => US [patent_app_date] => 2014-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 152199 [patent_no_of_claims] => 69 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14485620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16262519 [patent_doc_number] => 10753947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Methods for screening voltage-gated proteins [patent_app_type] => utility [patent_app_number] => 14/473386 [patent_app_country] => US [patent_app_date] => 2014-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 197 [patent_figures_cnt] => 197 [patent_no_of_words] => 66798 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 359 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14473386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9838518 [patent_doc_number] => 20150030599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-29 [patent_title] => 'ANTI-EGFR ANTIBODY AND ANTI-C-MET/ANTI-EGFR BISPECIFIC ANTIBODIES COMPRISING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/446167 [patent_app_country] => US [patent_app_date] => 2014-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 20374 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14446167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13151691 [patent_doc_number] => 10092548 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => Pharmaceutical compositions for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient [patent_app_type] => utility [patent_app_number] => 14/335895 [patent_app_country] => US [patent_app_date] => 2014-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 30 [patent_no_of_words] => 11193 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14335895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14005605 [patent_doc_number] => 10221239 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-05 [patent_title] => TRPM4 channel inhibitors for stroke treatment [patent_app_type] => utility [patent_app_number] => 14/392213 [patent_app_country] => US [patent_app_date] => 2014-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 18 [patent_no_of_words] => 13249 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14392213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10968113 [patent_doc_number] => 20140371146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'Glycoprotein Hormone Long-Acting Superagonists' [patent_app_type] => utility [patent_app_number] => 14/309317 [patent_app_country] => US [patent_app_date] => 2014-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14697 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14309317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13290743 [patent_doc_number] => 10156557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-18 [patent_title] => Calcium-binding photoprotein [patent_app_type] => utility [patent_app_number] => 14/291543 [patent_app_country] => US [patent_app_date] => 2014-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14367 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14291543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769393 [patent_doc_number] => 11401321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Method for determining mutateable ligand-GPCR binding at single amino acid resolution and pairs of mutated ligand and GPCR [patent_app_type] => utility [patent_app_number] => 14/897728 [patent_app_country] => US [patent_app_date] => 2014-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10949 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14897728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9670451 [patent_doc_number] => 20140234314 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/266387 [patent_app_country] => US [patent_app_date] => 2014-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 60 [patent_no_of_words] => 35724 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14266387 [rel_patent_id] =>[rel_patent_doc_number] =>)